key: cord-0269670-7wcvxwg6 authors: Crooks, C. M.; Weiler, A. M.; Rybarczyk, S. L.; Bliss, M. I.; Jaeger, A. S.; Murphy, M. E.; Simmons, H. A.; Mejia, A.; Fritsch, M. K.; Hayes, J. M.; Eickhoff, J. C.; Mitzey, A. M.; Razo, E.; Braun, K. M.; Brown, E. A.; Yamamoto, K.; Shepherd, P. M.; Possell, A.; Weaver, K.; Antony, K. M.; Morgan, T. K.; Newman, C. M.; Dudley, D. M.; Schultz-Darken, N.; Peterson, E.; Katzelnick, L. C.; Balmaseda, A.; Harris, E.; O’Connor, D. H.; Mohr, E. L.; Golos, T. G.; Friedrich, T. C.; Aliota, M. T. title: Prior dengue immunity enhances Zika virus infection of the maternal-fetal interface in rhesus macaques date: 2021-01-26 journal: bioRxiv DOI: 10.1101/2021.01.25.428184 sha: c4b39741eabe7170014f1231e57f5c197c1e0fc6 doc_id: 269670 cord_uid: 7wcvxwg6 Concerns have arisen that pre-existing immunity to dengue virus (DENV) could enhance Zika virus (ZIKV) disease, due to the homology between ZIKV and DENV and the observation of antibody-dependent enhancement (ADE) among DENV serotypes. To date, no study has examined the impact of pre-existing DENV immunity on ZIKV pathogenesis during pregnancy in a translational non-human primate model. Here we show that prior DENV-2 exposure enhanced ZIKV infection of maternal-fetal interface tissues in macaques. However, pre-existing DENV immunity had no detectable impact on ZIKV replication kinetics in maternal plasma, and all pregnancies progressed to term without adverse outcomes or gross fetal abnormalities detectable at delivery. Understanding the risks of ADE to pregnant women worldwide is critical as vaccines against DENV and ZIKV are developed and licensed and as DENV and ZIKV continue to circulate. NHP development and placentation resemble those of humans more closely than these 97 processes do in other animal models, making NHPs particularly relevant to understanding 98 viral infections in pregnancy (46). Here we apply our established NHP model (47) to assess 99 the impact of DENV immunity on ZIKV pathogenesis in pregnancy. We do not detect a role 100 for DENV immunity in modulating fetal outcomes in ZIKV-infected pregnant macaques. 101 However, previous exposure to DENV did appear to increase ZIKV infection in tissues of the 102 maternal-fetal interface, a result that warrants further examination. DENV-2 (orange). Approximately 1-3 months following DENV challenge, the eight DENV exposed macaques 106 were bred, became pregnant, and were challenged with 10 4 PFU ZIKV-PRVABC59, an Asian-lineage ZIKV 107 isolate, on gestational day 45. A cohort of four pregnant, DENV-naïve macaques (blue) were challenged with 108 ZIKV-PRVABC59 on gestational day 45. A control cohort of four macaques (green) were mock-challenged with 109 PBS on gestational day 45. All three cohorts underwent the same experimental protocols for blood collection 110 and sedation for ultrasound. At approximately gestational day 160, infants were delivered via cesarean section, 111 and a set of maternal-fetal interface tissues with maternal biopsies were collected. Infants were placed with 112 their mothers for long-term behavioral analysis, data from which is part of a separate study. 113 114 Prior DENV immunity does not modulate ZIKV replication kinetics in plasma 116 To characterize the range of pathogenic outcomes of congenital ZIKV infection in DENV-117 immune animals, we subcutaneously (s.c.) inoculated a cohort of eight non-pregnant, 118 Indian-origin rhesus macaques with 10 4 PFU of DENV-2/US/BID-V594/2006, a low-passage 119 human isolate from Puerto Rico (Fig. 1 ). All eight macaques were productively infected with 120 DENV-2, with peak plasma viral loads ranging from 10 5 -10 7 vRNA copies/mL occurring on 121 days 2-3 post-infection (Fig. 2) . Following a biphasic decline in viral loads, all macaques 122 cleared infection by day 11 post-infection. Following challenge, all three cohorts (DENV-immune, DENV-naïve, and mock) underwent 137 the same blood sampling and fetal monitoring protocols (Fig. 1 ). All macaques inoculated 138 with ZIKV were productively infected. Peak plasma viremia occurred on days 2-4 post-139 infection, with titers ranging from 10 4 -10 5 vRNA copies/mL in DENV-immune animals and 140 10 3 -10 5 vRNA copies/mL in DENV-naïve animals (Fig. 3A, 3B ). An unpaired t-test did not 141 reveal significant differences between cohorts in the peak, area under the curve, or duration 142 of viremia (Fig. 3C ). Since prolonged ZIKV viremia >21 days is only observed in pregnancy, 143 we assessed differences in duration both as a continuous variable and as a binary with 144 viremia greater than or less than 21 days. This suggests that prior DENV-2 immunity did not 145 alter ZIKV replication kinetics during gestation. were challenged with 10 4 PFU of ZIKV-PRVABC59 at gestation day 45, which is late in the first trimester. Viral 150 loads were assessed from plasma samples with ZIKV-specific QRT-PCR. All values above the limit of 151 quantification (100 copies vRNA, mL plasma) are shown above. C. Graphs of the values for the peak, duration, 152 and area under the curve of viremia for both DENV-immune and DENV-naïve macaques. An unpaired t-test 153 was used for statistical comparison; ns = not significant (p > 0.05). Only values above the limit of quantification 154 were used in statistical analyses. For DENV-1-4, specific antibody titer ranges have been shown to enhance viral replication. As measured by a DENV inhibition ELISA (iELISA) assay, an intermediate antibody titer 160 range of 1:21-1:80 was associated with a greater risk of developing severe dengue disease 161 upon secondary exposure in a human cohort study (2). In a separate human cohort study, a 162 plaque reduction neutralization test (PRNT50) titer of <1:100 was associated with an 163 increased risk of severe DENV disease upon secondary exposure (48). In order to assess 164 how cross-reactive DENV antibodies impact ZIKV outcomes during pregnancy, we in DENV-immune macaques than DENV-naïve animals 28-35 days after ZIKV challenge, but 210 no significant differences were noted in PRNT90 titers between groups. Together, these 211 data provide evidence that antibodies capable of cross-reacting with ZIKV were present at in blue. Samples labeled "ND" were not detected. Using an unpaired t-test, PRNT50, but not PRNT90, titers 220 from the DENV-immune group were significantly higher than the PRNT50 titer of DENV-naïve animals at 28 221 days post-ZIKV-challenge (**p<0.01). Neutralization curves can be found in Supplementary Fig. 1 . diameter of the mock-infected cohort was significantly lower than the normative data 236 (p=0.01713). There were no significant differences noted in pairwise comparisons of growth 237 trajectories between groups. Taken together, these extensive fetal growth measurements 238 suggest that there was no significant reduction in fetal growth in ZIKV-exposed macaques, 239 regardless of their DENV immune history. Table 1 ). Fetal tissues are not available for virological analysis because 248 infants were placed with their mothers for long-term behavioral analysis, data from which 249 will be part of a forthcoming study. We collected fetal plasma, umbilical cord plasma, and Table 1 ). There was no robust evidence to support direct infection of fetal health and perform four measurements of fetal growth: biparietal diameter and head circumference to 257 evaluate head size; abdominal circumference and femur length to evaluate overall fetal growth. Using 258 normative data from the California National Primate Research Center, a z-score was calculated for each 259 measurement and the change in z-score from baseline is plotted for each measurement with an open circle. 260 The overall growth trajectory for each group was quantified by calculating the regression slope parameters 261 from baseline (solid line). When compared to the normative data, mock-infected animals had significantly 262 reduced biparietal diameter growth (p=0.01713). No other significant differences were detected in 263 comparisons to the normative data or in comparisons between the experimental groups. 264 265 Enhanced infection of the maternal-fetal interface in DENV-immune macaques 266 We performed an extensive dissection of both discs of the placenta in order to understand 267 the distribution of ZIKV in placental tissues. Positive tissue samples were detected above Abdominal Circumference (z-score) To determine whether the presence of vRNA in the MFI was associated with duration, peak, immune cohort (Fig. 6C ). There was a significant correlation between area under the curve 287 and presence of vRNA in the MFI in both cohorts (Fig. 6D, 6E ). There was a significant also present in mock-infected animals. There were no statistically significant differences 324 between any of the groups for any of these pathologic features or placental weight. This We did observe an association between prolonged viremia, defined as lasting >21 days, and tempting to speculate that prior DENV immunity may lead to longer viral replication and 357 therefore greater ZIKV burden in the placenta. However, since we did not observe any 358 statistically significant differences in the duration of viremia between the two groups, perhaps due to a small sample size, we cannot make any definitive conclusions about the 360 impact of prior DENV immunity on the duration of ZIKV viremia. serotypes has an effect on subsequent enhancement or protection (for review see (20) ). There is also considerable evidence that the pre-existing antibody titer at the time of Tissues were dissected as previously described (47) using sterile instruments that were 590 changed between each organ and tissue type to minimize possible cross contamination. Each organ/tissue was evaluated grossly, dissected with sterile instruments in a sterile 592 culture dish, and sampled for histology, viral burden assay, and/or banked for future assays. A comprehensive listing of all specific tissues collected and analyzed is presented in Fig. 6A 594 (maternal-fetal interface tissues) and Supplementary Immune Response to Dengue and Zika Antibody-dependent enhancement of severe dengue 662 disease in humans Dengue viruses and mononuclear 664 phagocytes. I. Infection enhancement by non-neutralizing antibody Prospects for a 667 dengue virus vaccine Dengue Antibody-Dependent Enhancement: Knowns and 669 Antibodies for Infectious Diseases Cross-reactive dengue human monoclonal 674 antibody prevents severe pathologies and death from Zika virus infections Enhancement of Zika virus pathogenesis by preexisting antiflavivirus 678 immunity Dengue virus (DENV)-specific antibodies enhance Brazilian Zika virus (ZIKV) 682 infection A relevant in vitro human 685 model for the study of Zika virus antibody-dependent enhancement Human antibody responses after dengue 690 virus infection are highly cross-reactive to Zika virus Dengue immune sera enhance Zika virus infection in human peripheral 694 blood monocytes through Fc gamma receptors Dengue virus sero-cross-reactivity drives 698 antibody-dependent enhancement of infection with zika virus Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective 703 against Zika Virus Lack of Durable Cross-Neutralizing Antibodies Against Zika 706 Virus from Dengue Virus Infection Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue 711 Virus Infection in Asia and the Americas A Human Antibody Neutralizes Different 714 Flaviviruses by Using Different Mechanisms reactive Dengue virus-specific CD8 + T cells protect against Zika virus during pregnancy Dengue virus-reactive CD8 + T cells mediate cross-protection against 721 subsequent Zika virus challenge Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection Protective and enhancing interactions 727 among dengue viruses 1-4 and Zika virus Impact of preexisting dengue immunity on Zika virus 733 emergence in a dengue endemic region Prior Dengue Virus Infection Is Associated With 736 Increased Viral Load in Patients Infected With Dengue but Not Zika Virus. Open Forum 737 Infect Dis 6: 738 23 Prior dengue virus infection and risk of Zika: A pediatric cohort in 741 Nicaragua Comprehensive Immunoprofiling of Pediatric Zika Reveals 745 Key Role for Monocytes in the Acute Phase and No Effect of Prior Dengue Virus 746 Infection Evolution of the innate and adaptive immune response in women with 751 acute Zika virus infection Impact of prior flavivirus immunity on Zika virus 756 infection in rhesus macaques Zika virus pathogenesis in rhesus macaques is 760 unaffected by pre-existing immunity to dengue virus Primary infection with dengue or Zika virus does not affect the severity 766 of heterologous secondary infection in macaques Therapeutic and 769 protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. Nat 770 Med 771 30. Cao-Lormeau Recent emergence of dengue virus serotype French Polynesia results from multiple introductions from other South Pacific Islands 776 Epidemic of dengue-4 virus in Yap State, Federated States of Micronesia, and 777 implication of Aedes hensilli as an epidemic vector An outbreak of 779 dengue fever in Yap State Grangeon, and 781 A. C. Gourinat. 2015. Co-infection with Zika and dengue viruses in 2 patients, New 782 Caledonia Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental 787 Zika virus infection in human placental tissue explants is 790 enhanced in the presence of dengue virus antibodies in-vitro Dengue Virus Immunity Increases Zika 795 Virus-Induced Damage during Pregnancy Maternal 797 immunity and antibodies to dengue virus promote infection and Zika virus-induced 798 microcephaly in fetuses Maternal Zika Virus Disease Severity Prior Dengue Antibodies, and Their Relationship to Birth Outcomes Neutralizing Antibody Titers in Maternal Sera, Northeastern Brazil Perinatal 812 analyses of Zika-and dengue virus-specific neutralizing antibodies: A microcephaly 813 case-control study in an area of high dengue endemicity in Brazil Association 816 of past dengue fever epidemics with the risk of Zika microcephaly at the population level 817 in Brazil Zika Virus Vaccine 819 Development: Progress in the Face of New Challenges Structural basis of 823 potent Zika-dengue virus antibody cross-neutralization The bright and 825 the dark side of human antibody responses to flaviviruses: lessons for vaccine design Dengvaxia sensitizes seronegatives to vaccine enhanced disease 828 regardless of age Macaque monkeys in Zika virus 830 research: 1947-present Highly efficient maternal-fetal Zika 838 virus transmission in pregnant rhesus macaques Reconstruction of antibody dynamics and infection histories to evaluate dengue risk Zika 848 virus infection enhances future risk of severe dengue disease Prenatal growth in the cynomolgus and 854 rhesus macaque (Macaca fascicularis and Macaca mulatta): A comparison by 855 ultrasonography Ultrasound Imaging in Rhesus (Macaca Mulatta) and Long-Tailed 857 (Macaca fascicularis) Macaques. Reproductive and Research Applications. The 858 Laboratory Primate ACOG Practice Bulletin No. 204: fetal growth 860 restriction Microbial Vertical 862 Transmission during Human Pregnancy Delayed childhood neurodevelopment and 868 neurosensory alterations in the second year of life in a prospective cohort of ZIKV-869 exposed children African-lineage Zika virus 875 replication dynamics and maternal-fetal interface infection in pregnant rhesus macaques Multiplex PCR method for MinION 882 and Illumina sequencing of Zika and other virus genomes directly from clinical samples A rhesus macaque model of Asian-896 lineage Zika virus infection Immune clearance of highly pathogenic SIV infection Zika 905 viruses of African and Asian lineages cause fetal harm in a mouse model of vertical 906 transmission Serum dilution neutralization 908 test for California group virus identification and serology High seroprevalence of antibodies against dengue virus in a 912 prospective study of schoolchildren in Serological diagnosis of dengue by an ELISA 915 inhibition method (EIM) Techniques for hemagglutination and 917 hemagglutination-inhibition with arthropod-borne viruses A simple method of estimating fifty per cent 920 endpoints Comparison of four serological 923 methods and two reverse transcription-PCR assays for diagnosis and surveillance of 924 Zika virus infection Specificity, cross-929 reactivity, and function of antibodies elicited by Zika virus infection A. formal analysis, investigation, writing -review and editing contributed data curation, formal analysis, investigation, methodology, writing -976 review and editing contributed conceptualization, methodology, writing -review and editing 978 contributed conceptualization, methodology, project administration, writing -review 979 and editing contributed investigation, project administration, writing -review and editing 982 contributed methodology, project administration, writing -review and editing 983 A.B. contributed data curation, methodology, writing -review and editing contributed methodology, project administration, writing -review and editing 985 contributed conceptualization, data curation, funding acquisition, methodology, 986 project administration, resources, software, supervision, writing -review and editing 987 contributed conceptualization, data curation, funding acquisition, methodology, 988 project administration, resources, supervision, writing -review and editing G contributed conceptualization, data curation, funding acquisition, methodology, 990 project administration, resources, supervision, writing -review and editing contributed conceptualization, data curation, funding acquisition, methodology, 992 project administration, resources, supervision, writing -review and editing A contributed conceptualization, data curation, funding acquisition, investigation, 994 methodology, project administration, resources, supervision, writing -review and editing 995 996 Competing interests: The authors declare no competing interests 1000 denv-on-zikv-during-pregnancy-in-macaques. Primary data that support the findings of this 1001 study will be available in the future at the Zika Open Research Portal 1002 BioProject accession number 1006 PRJNA435432. Raw FASTQ reads of the challenge stock of ZIKV PRVABC59 are available 1007 at the Sequence Read Archive, BioProject accession number PRJNA392686. The authors 1008 declare that all other data supporting the findings of this study are available within the article 1009 and its supplementary information files Research Center (WNPRC) for their contributions to this study. We thank Brandy Russell for 937 providing virus isolates. The following reagent was obtained through BEI Resources, NIAID,